. Author manuscript; available in PMC: 2013 Jun 3.

Published in final edited form as: Biol Blood Marrow Transplant. 2010 May 26;16(11):1576–1581. doi: 10.1016/j.bbmt.2010.05.008

Table 2.

Clinical Characteristics of Three Severe Cases of VREB in the Early Post-HSCT Period

	Age/sex	Underlying Disease	Transplant Type	Donor	Onset of VREB	Clinical Presentation	Duration of Bacteremia	Hospital Course	Copathogens	Treatment for VRE^*	Outcome
1.	57/F	ALL	Cord	MM	day +4	fever, delirium, hypoxia diarrhea	18 days	progressive decline in mental status, bibasilar lung consolidation, VDRF, persistent bacteremia	None	Daptomycin,^† gentamicin tigecycline	died day + 21
2.	68/F	AML	TCDPBSCT	MUD	day +6	fever, confusion, hypoxia, diarrhea	1 day and 3 days	progressive decline in mental status, bilateral GG infiltrates, VDRF, renal failure, recurrent bacteremia	None	Linezolid	died day + 36
3.	65/F	MDS	TCDPBSCT	MM	day +6	fever, change in mental status, hypoxia and bloody diarrhea	3 days	progressive decline in mental status, interstitial lung infiltrates, VDRF, tracheostomy	None	Linezolid	Alive, late graft failure

TCDPBSCT indicates T cell-depleted peripheral blood stem cell transplant; MM, mismatched; MUD, matched unrelated donor; VDRF, ventilator dependent respiratory failure; GG, ground glass; HSCT, hematopoietic stem cell transplantation; VREB, vancomycin-resistant Enterococcus bacteremia.

All patients underwent prompt catheter removal.

^†

For linezolid resistant VRE, Daptomycin dose 4–6 mg/kg every 24 hours, Gentamicin 1 mg/kg every 12 hours (renally adjusted dose).